Swiss National Bank Amylyx Pharmaceuticals, Inc. Transaction History

Swiss National Bank

  • $143 Billion
  • Q2 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024
BUY
$2.71 - $19.57 $18,699 - $135,033
6,900 Added 8.66%
86,600 $245,000
Q4 2023

Feb 06, 2024
BUY
$12.07 - $18.46 $159,324 - $243,672
13,200 Added 19.85%
79,700 $1.17 Million
Q3 2023

Nov 08, 2023
BUY
$18.08 - $23.45 $19,887 - $25,795
1,100 Added 1.68%
66,500 $1.22 Million
Q2 2023

Aug 09, 2023
BUY
$20.98 - $31.42 $1.37 Million - $2.05 Million
65,400 New
65,400 $1.41 Million

Others Institutions Holding AMLX

# of Institutions
139
Shares Held
46.5M
Call Options Held
226K
Put Options Held
909K
View Full List

About Amylyx Pharmaceuticals, Inc.

AMLX Quotes by TradingView
  • Ticker AMLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,533,200
  • Market Cap $290M
  • Description
  • Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...
More about AMLX
Track This Portfolio

Track Swiss National Bank Portfolio

Follow Swiss National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email